UBE2O and prostate cancer: Cox’s proportional hazard modelling for UBE2O expression also identified that UBE2O immunohistochemical staining correlated with clinical recurrence free survival (p < 0.001) and overall survival (p < 0.05) in prostate cancers (Table 6 and Table 7).